Our stem cell research has resulted in technology that allows us to produce commercial quantities of human neural stem cells with the ability to control the differentiation of the cells into multiple kinds of human neurons and glia. Neuralstem's spinal cord stem cells are the subject of the first FDA-approved  neural stem cell trial to treat Amyotrophic Lateral Sclerosis, (ALS or Lou Gehrig's disease). Once approved by the FDA, these and other Neuralstem cell lines could be used to treat currently incurable CNS diseases.